KV Pharma Reaches $12.8M Deal To Settle Shareholder Action

Law360, New York (March 20, 2014, 5:52 PM EDT) -- KV Pharmaceutical Co. and the lead plaintiffs in a securities class action alleging the drugmaker hid U.S. Food and Drug Administration violations to inflate its share price have reached a $12.8 million settlement agreement that, if approved, would end more than five years of litigation, according to a filing in Missouri federal court Wednesday.

Lawyers for Norfolk County Retirement System and the State-Boston Retirement System, the court-appointed lead plaintiffs in the suit, asked a Missouri federal court Wednesday to approve the settlement, saying the amount was appropriate and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.